<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658524</url>
  </required_header>
  <id_info>
    <org_study_id>3.138.270</org_study_id>
    <nct_id>NCT04658524</nct_id>
  </id_info>
  <brief_title>Evaluation of Thyroid Function in Patients With Chronic Kidney Disease</brief_title>
  <official_title>Evaluation of Thyroid Function in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rio de Janeiro State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rio de Janeiro State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A higher prevalence of thyroid disease has been associated with chronic kidney disease (CKD),&#xD;
      and subclinical hypothyroidism seems to be the most common dysfunction. The aim is to&#xD;
      evaluate thyroid function and autoimmunity in patients with CKD stages 3, 4 and 5.&#xD;
      Cross-sectional study to be carried out on patients with stages 3 and 4 in a Nephrology&#xD;
      outpatient clinic. Thyroid function is evaluated by measuring thyroid stimulating hormone&#xD;
      (TSH), free thyroxine, free triiodothyronine and antithyroperoxidase antibodies (TPOAb)&#xD;
      levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cross-sectional study to be carried out on patients with stages 3, 4 and 5 in a Nephrology&#xD;
      outpatient clinic. Thyroid function is evaluated by measuring thyroid stimulating hormone&#xD;
      (TSH), free thyroxine, free triiodothyronine and antithyroperoxidase antibodies (TPOAb)&#xD;
      levels. Free Thyroxine (FT4) will be measured by liquid chromatography tandem mass&#xD;
      spectrometry and electrochemiluminescence immunoassay in order to compare methods in this&#xD;
      population.&#xD;
&#xD;
      The glomerular filtration rate was estimated (eGFR) by the Chronic Kidney Disease&#xD;
      Epidemiology Collaboration formula (CKD-EPI), and the CKD stages were defined according to&#xD;
      the Kidney Disease Improving Global Outcomes directives (KDIGO).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Free thyroxine (FT4) levels in chronic kidney disease</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Free thyroxine levels through two different methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TSH levels in chronic kidney disease</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>TSH levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of thyroid antibodies in chronic kidney disease</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>antithyroperoxidase and antitireoglobulin antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free triiodothyronine (FT3) levels in chronic kidney disease</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>T3 levels</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Thyroid Dysfunction</condition>
  <arm_group>
    <arm_group_label>Chonic kidney disease stages 3, 4 and 5</arm_group_label>
    <description>Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thyroid function</intervention_name>
    <description>laboratorial thyroid tests</description>
    <arm_group_label>Chonic kidney disease stages 3, 4 and 5</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic kidney disease patients followed in a Nephrology outpatient clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients over 18 years old with CKD stages 3 and 4 were included in the&#xD;
        study.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria: 1) acute systemic inflammatory disease; 2) pituitary disease in the&#xD;
        past or present; 3) regular treatment with amiodarone, lithium, interferon,&#xD;
        immunosuppressive drugs and glucocorticoids; 4) previously diagnosed hypothyroidism and&#xD;
        undergoing levothyroxine replacement.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Ana Beatriz Winter Tavares</name>
      <address>
        <city>Petr√≥polis</city>
        <state>RJ</state>
        <zip>25665-442</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinol Diabetes Obes. 2016 Oct;23(5):407-15. doi: 10.1097/MED.0000000000000275. Review.</citation>
    <PMID>27428519</PMID>
  </reference>
  <reference>
    <citation>Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol. 2012 Jan;23(1):22-6. doi: 10.1681/ASN.2010070766. Epub 2011 Oct 21. Review.</citation>
    <PMID>22021708</PMID>
  </reference>
  <reference>
    <citation>Meuwese CL, Gussekloo J, de Craen AJ, Dekker FW, den Elzen WP. Thyroid status and renal function in older persons in the general population. J Clin Endocrinol Metab. 2014 Aug;99(8):2689-96. doi: 10.1210/jc.2013-3778. Epub 2014 Apr 15.</citation>
    <PMID>24735423</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rio de Janeiro State University</investigator_affiliation>
    <investigator_full_name>Ana Beatriz Winter Tavares</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

